NeuroKine Therapeutics (NKT), LLC, is a clinical stage drug development company focused on clinical assets for serine/threonine protein kinase targets. Assets are from a technology platform that delivers de-risked candidates from basic research to early clinical development.
NKT is a Columbia-Northwestern University academic spin-out that employs lean biotech operational principles. Lean biotech business operations use reduced personnel costs, just-in-time business practices, certified contract organizations skilled in meeting development milestones, and academic collaborator interactions. The goal is asset de-risking and clinical evaluation.
Non-dilutive support is via peer reviewed funding from the National Institutes of Health (e.g., STTR AG062095 & SBIR AG071388) and disease-related foundations (e.g., Alzheimer's Association and Alzheimer Drug Discovery Foundation).
USA and International patents cover matter and indications, providing a robust intellectual property foundation.
In the CNS disease domain, an emphasis is on the common yet neglected pathophysiology progression theme of synaptic dysfunction and neuroinflammation.